TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Not Sold on AVI BioPharma... Yet VFC submits: Avi BioPharma, Inc. (AVII) is back on the radar of late, after releasing some positive news reports. On Monday morning Avi announced that it had landed a government contract with the U.S. Defense Threat Reduction Agency [DTRA] for the development of AVI-7100 (formerly identified as AVI-7367) as a medical countermeasure to a possible H1N1 virus pandemic outbreak. The contract could be worth up to $18 million. Just two months earlier, AVI had announced a similar agreement with the DTRA, with that contract being worth up to $4 million.Last week Avi also announced the positive results of a Phase 1b-2 clinical study for the company's drug treatment for Duchenne muscular dystrophy [DMD]. The study included 28 patients and was well tolerated by all, according to reports issued by the company.Complete Story » seekingalpha.com |
BioClinica Announces Second Quarter 2010 Financial Results (Business Wire) NEWTOWN, Pa.----BioClinica™, Inc. , a global provider of clinical trial management services, today announced its financial results for the second quarter and six months ended June 30, 2010. us.rd.yahoo.com |
St. Jude Medical In Settlement Talks St. Jude Medical is in settlement talks with the Justice Department regarding allegations the heart-device maker used medical studies to pay kickbacks and boost product usage. online.wsj.com |
Aetna CEO to Retire Aetna Chairman and CEO Ronald A. Williams will step down as CEO next month, to be succeeded by President Mark T. Bertolini. online.wsj.com |
Abbott Laboratories Shares 'Marked Down' - Good Time to Buy? Roger I. McNamara submits: Over several decades a fixture in both its Industry and the larger market/economy, Abbott Labs (ABT) has been tagged with a share price markdown in recent weeks. From the low-mid 50's of not long ago it now struggles to hold onto $47, slightly over 5% atop its 52 week closing low but fully 17% beneath its 52 week best. Similarly as with both 50 and 200 day moving averages north of 50, the stock is now offered at noticeable discounts. What has brought this about, and what should the savvy investor do about it?Among the pharmaceutical entrants ABT has stood aside with a fairly low --- either side of 60% --- revenue component derived from prescription compounds, the remainder faithfully arriving through nutritional supplements and an assortment of diagnostic and testing devices aimed at vascular and other health shortcomings. Put another way, its product slate is comparatively diversified. It has nonetheless been widely noticed and documented that the company's pipeline of life-supporting medications had become weak, or, as one commentator cleverly put it, ABT was not delivering enough "shots on goal" toward the Food and Drug Administration's net minders, who in the meantime have grown more demanding and selective before escorting a new member through Phase III clinical trials. In addition to bolstering research and development outlays, Abbott's management elected to mobilize its fortress balance sheet, sporting $12.68 net current assets per share at year end 2009, toward buying its way to a prosperous future.Complete Story » seekingalpha.com |